Affymetrix (AFFX) 8.39 $AFFX
Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018
M2 - Fri Aug 01, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ct68hv/global_single) has announced the addition of the "Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018" report to their offering. Single Nucleotide Polymorphism (SNP) genotyping is the screening and analysis of genetic variations of SNPs in the genome of various species. SNPs are commonly present in all species including humans. SNP genotyping and analysis technology can analyze thousands of SNPs and has the potential for whole-genome genotyping. It is the most common genetic variation that occurs in the genetic makeup. It is an emerging field in life science, which provides an in-depth analysis of SNPs. It is generally used by researchers for genomics study. It has a broad range of applications in several industries such as Pharmaceuticals and Pharmacogenomics, Diagnostics Research, Agriculture Biotechnology, and Breeding and Animal Livestock. There are several technologies which are used for SNP genotyping and analysis such as SNP GeneChips and microarrays, TaqMan allelic discrimination, SNP by pyrosequencing, SNPlex, and MassARRAY Matrix-assisted Laser Desorption/Ionization-Time-of-Flight. The analysts forecast the Global SNP Genotyping and Analysis market to grow at a CAGR of 20.65 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Market Segmentation by Application 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - Affymetrix Inc. - Illumina Inc. - F. Hoffmann-La Roche Ltd. - Thermo Fisher Scientific Inc. - Agilent Technologies Inc. - Douglas Scientific Llc. - Fluidigm Corp. - Luminex Corp. - PREMIER Biosoft Intl. - Promega Corp - Qiagen N. V. - Sequenom Inc. - WaferGen Biosystems Inc. For more information visit http://www.researchandmarkets.com/research/ct...bal_single
Affymetrix Reports Second Quarter 2014 Operating Results
Business Wire - Thu Jul 31, 3:00PM CDT
Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the second quarter of 2014.
Appointments, New Orders, and Program Expansions - Research Reports on NQ Mobile, Plug Power, Zhone Technologies, Proofpoint and Affymetrix
PR Newswire - Wed Jul 23, 7:10AM CDT
Today, Analysts Review released its research reports regarding NQ Mobile Inc. (NYSE: NQ), Plug Power Inc. (NASDAQ: PLUG), Zhone Technologies Inc. (NASDAQ: ZHNE), Proofpoint, Inc. (NASDAQ: PFPT) and Affymetrix Inc. (NASDAQ: AFFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5017-100free.
Global Transcriptomics Market 2014-2018 with Abbott, Affymetrix, Agilent Technologies, F. Hoffman-La Roche, Illumina & Thermo Fisher Scientific Dominating
M2 - Mon Jul 21, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbvfc/global) has announced the addition of the "Global Transcriptomics Market 2014-2018" report to their offering. The Global Transcriptomics market will grow at a CAGR of 15.8 percent over the period 2013-2018. Transcriptomics studies involve the collection and analysis of transcriptomes of different types of cells or tissues of organism. A transcriptome represents the set of all RNA molecules, which is a small part of the genetic code. The variation in genetic expression characterizes the extensive range of physical and biochemical differences among various cells and tissues and may lead to disease. It helps researchers to understand transcriptional activity in disease cause. Transcriptomics includes four prominent technologies: Microarrays, PCR, RNAi Gene Silencing Technology, and NGS technologies. This report covers the present scenario and the growth prospects of the Global Transcriptomics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of products used for research and diagnostics. The products employed in the use microarray, PCR, NGS and RNAi techniques are considered within the scope of the report. The report, the Global Transcriptomics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions with individual country-wise revenue segmentation; it also covers the Global Transcriptomics market landscape and its growth prospects in the coming years. The report also includes a share of the key vendors operating in this market. Key Vendors - Abbott Laboratories - Affymetrix Inc. - Agilent Technologies Inc. - F. Hoffmann-La Roche Ltd. - Illumina Inc. - Thermo Fisher Scientific Inc. Other Prominent Vendors - Biological Industries Ltd. - Bio-Rad Laboratories Inc. - Cytognomix Inc. - Kreatech Inc. - Molecular Devices LLC - Oxford Gene Technology Ltd. - Qiagen N. V. - SciGene Corp. - Sigma-Aldrich Co. LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/4kbvfc/global
New Licenses, Conference Call Schedules, and Partnerships to Lead Marketing Strategies - Analyst Notes on NetEase, Lattice Semiconductor, Cypress, Affymetrix and ChannelAdvisor
PR Newswire - Thu Jul 10, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding NetEase.com, Inc. (NASDAQ: NTES), Lattice Semiconductor Corporation (NASDAQ: LSCC), Cypress Semiconductor Corporation (NASDAQ: CY), Affymetrix Inc. (NASDAQ: AFFX) and ChannelAdvisor Corporation (NYSE: ECOM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4630-100free.
Shares of AFFX Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 09, 9:24AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on May 12th, 2014 at $7.88. In approximately 2 months, Affymetrix has returned 13.90% as of today's recent price of $8.97.
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Global Flow Cytometry Market Forecasts and Opportunities, 2018: Technology, Products & Services, Application & End User Analysis
M2 - Tue Jul 08, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xsvbl6/flow_cytometry) has announced the addition of the "Global Flow Cytometry Market Forecasts and Opportunities, 2018: Technology, Products & Services, Application & End User Analysis" report to their offering. In this report, the global flow cytometry market has been segmented on the basis of products (instruments, reagents and consumables, software, services, and accessories) and applications (research, clinical, and industrial applications). The Research field commands a major chunk of the global flow cytometry market in 2013. This is attributed to the increasing applications of flow cytometry in drug discovery and development process, right from pre-clinical trials to target identification and throughput screening. However, the clinical applications segment is the fastest growing segment in this market, owing to the increasing prevalence coupled with intensifying adoption of flow cytometry techniques for the diagnosis and treatment of a number of diseases such as cancer, HIV/AIDS, and others. The global flow cytometry market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period (2013-2018). However, the Asia-Pacific region is expected to grow at the highest CAGR of 16% from 2013 to 2018. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as various economic developments and growing prevalence to HIV/AIDS, growing number of research initiatives, increasing government support, growing awareness, and growing focus of both international and domestic players are driving the growth of the market in the Asia-Pacific region. New product launches is the key strategy followed by the leading market players to ensure their growth in the market. Moreover, partnerships, agreements, collaborations and joint ventures, mergers and acquisitions, and expansions are some other growth strategies adopted by the industry players in the global market. Scope Technology - Cell-Based - Bead-Based Products & Services - Reagents - Instruments - Software - Accessories Application - Research - Clinical End User - Commercial Organizations - Diagnostics Laboratories Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Trends 6 Technology 7 Product 8 Application 9 End User 10 Geography 11 Competitive Landscape 12 Company Profiles - Beckman Coulter, Inc. (A Subsidiary Of Danaher Corporation) - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc. - Ebioscience, Inc. (A Subsidiary Of Affymetrix, Inc.) - Emd Millipore Corporation (A Division Of Merck Kgaa) - Life Technologies Corporation (A Brand Of Thermo Fisher Scientific, Inc.) - Luminex Corporation - Miltenyi Biotech - Partec Gmbh - Ttp Labtech Ltd. For more information visit http://www.researchandmarkets.com/research/xs..._cytometry
Synta Pharmaceuticals (SNTA) Jumps: Stock Rises 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 8:21AM CDT
Synta Pharmaceuticals Corp. (SNTA) was a big mover last session, as the company saw its shares rise by almost 8% on the day.
Affymetrix to Report Second Quarter 2014 Operating Results on Thursday July 31, 2014
Business Wire - Mon Jul 07, 5:00AM CDT
Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will report operating results for the second quarter of 2014 after market close on Thursday July 31, 2014. The company will hold a conference call on the same day at 5:00pm ET.
Genomic Grows on Breast Cancer Test, Margin Pressure Continues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 1:30PM CDT
On Jul 3, we issued an updated research report on Genomic Health Inc. (GHDX).
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Global Molecular Cytogenetics Market 2014-2018 with Abbott Labs, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina & PerkinElmer Dominating
M2 - Wed Jul 02, 2:03PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ssrz43/global_molecular) has announced the addition of the "Global Molecular Cytogenetics Market 2014-2018 with Abbott Labs, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina & PerkinElmer Dominating" report to their offering. The Global Molecular Cytogenetics Market will grow at a CAGR of 23.51% to 2018 This report covers the present scenario and the growth prospects of the Global Molecular Cytogenetics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of products used in molecular cytogenetics. The products employed in the use of FISH and aCGH techniques are considered within the scope of the report. The increase in the incidence of genetic disorders is one of the major drivers. Genetic disorders such as Down syndrome, fragile X syndrome, tuberous sclerosis, and other genetic and chromosomal disorders have increased the demand for cytogenetic diagnostic kits and technology. Molecular cytogenetic techniques can be used in personalized medicines for the early detection of diseases and selection of appropriate treatment, integration of molecular diagnostics with therapeutics, and monitoring therapy, as well as determining the prognosis. At present, cytogenetic analysis allows the study of essential biological problems such as the nature of inherited syndromes and genomic variations, which are responsible for carcinogenesis and 3D organization of the human genome. Identification and validation of the genetic composition of an individual plays a major part in ascertaining health and susceptibility to common diseases such as heart disease and cancer. The awareness of genetic diseases is helping in the development of personalized medicines, which are focused on targeted drug development. Genetic profiling of patients helps in defining an individual's risk for clinical outcomes and his/her response to specific drugs. Personalized medicines are highly effective and help improve the health of a patient. Further, the report states that one of the major challenges in the market is the lack of knowledge about genomics among doctors and researchers, which leads to misinterpretation of the genetic data of an individual. Key Vendors - Abbott Laboratories - Affymetrix Inc. - Agilent Technologies Inc. - F. Hoffmann-La Roche Ltd - Illumina Inc. - PerkinElmer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/ss..._molecular
Dicerna Pharmaceuticals (DRNA) Soars: Stock Rises 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:39AM CDT
Dicerna Pharmaceuticals, Inc. (DRNA) was a big mover last session, as its shares rose almost 20% on the day.
Curis (CRIS) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:51AM CDT
Curis, Inc. (CRIS) was a big mover last session, as its shares rose over 11% on the day.
BIND Therapeutics (BIND) Soars: Stock Adds 9.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:39AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as its shares rose over 9% on the day.
Dyax Corp. (DYAX) Soars: Stock Rises 12.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 7:51AM CDT
Dyax Corp. (DYAX) was a big mover last session, as its shares rose nearly 13% on the day.
Affymetrix Up 14.7% Since SmarTrend Uptrend Call (AFFX)
Comtex SmarTrend(R) - Fri Jun 27, 11:49AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on May 12th, 2014 at $7.88. In approximately 2 months, Affymetrix has returned 14.67% as of today's recent price of $9.03.
Earnings Estimates Moving Higher for Affymetrix (AFFX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:40AM CDT
Affymetrix could be a solid choice for investors, as it witnessed solid earnings estimate revision activity and also has a favorable Zacks Rank.
Cell Culture: The Market for Media, Sera and Reagents to 2017
M2 - Thu Jun 26, 2:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pqnpcm/cell_culture_the) has announced the addition of the "Cell Culture: The Market for Media, Sera and Reagents" report to their offering. The choice of cells to use in biopharmaceutical production depends on a number of factors, some technical and some economic. Bacteria and yeast, for instance, are relatively simple to grow. Each cell of a bacterium or yeast is an independent organism capable of its own metabolism. Yeasts and bacteria have fairly simple nutritional needs and grow well suspended in a liquid medium, as well as in large fermentors. This report is focused on cell culture used in the research and production of biopharmaceuticals. In the pharmaceutical industry, cell culture is a major foundation of biopharmaceutical development, bioprocessing and manufacturing. Biopharmaceutical products are developed from large, complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. As growing cells for biopharmaceutical production is slow, expensive and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals. Forecasts and current market sizing are provided in three specific segments: Media, Sera, and Reagents exhaustive report provides specific information on: - Market Size, of the Cell Culture Media Segment Market, Sera Segment Market and Reagent Segment Market through 2017 - Market Share Estimate for Animal-Derived, Component Free Media - Market Share Estimate for Serum-Free Media - Market Share Estimate for Chemically-Defined Media - Competitive Market Share by leading supplier as of 2012 - Estimated Market by Region (North America, Europe, Asia U.S.) - Key Market Drivers and Restraints for suppliers, including discussions of biopharmaceutical pipelines, biomedical R&D directions, and the future of transgenic plant and animal production. - Review of the various expression systems (Bacteria, Yeast, Insect, and Mammal) and the biopharmaceutical product manufactured by these systems The report contains a discussion of the preferences in media types vying for dominance in the market, including the following: - ADCF - animal derived component free media - CD - chemically defined media - CSFM - complete serum free medium - PF - protein free media - SF - serum free media - SFM - serum free medium Key Topics Covered: CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER TWO: GENETICALLY MODIFIED CELLS FOR BIOPHARMACEUTICAL DEVELOPMENT CHAPTER THREE: CELL CULTURE TECHNOLOGY CHAPTER FOUR: CELL CULTURE MARKET CURRENT AND FUTURE TRENDS CHAPTER FIVE: COMPANY PROFILES - Advanced Biotechnologies, Inc. - Affymetrix, Inc. - AMRESCO, Inc. - Atlanta Biologicals, Inc. - BD Biosciences - Bioreclamation Inc - Cell Essentials, Inc. - CellGenix Technologie Transfer GmbH - ClonTech Laboratories, inc. - Corning Life Sciences - EMD Millipore - GE Healthcare Live Sciences - Gemini Bio-Products - Invitria - Irvine Scientific - J R Scientific, Inc. - Life Technologies Corporation - Lonza Bioscience - MP Biomedicals - Novozymes Biopharma US Inc - PromoCell GmbH - Quality Biological, Inc. - R&D Systems, Inc. - SAFC Biosciences - SBH Sciences - Selexis SA - SeraCare Life Sciences, Inc. - Sera Laboratories International Ltd - Stemcell Technologies Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/pq...ulture_the
Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018
M2 - Fri Aug 01, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ct68hv/global_single) has announced the addition of the "Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018" report to their offering. Single Nucleotide Polymorphism (SNP) genotyping is the screening and analysis of genetic variations of SNPs in the genome of various species. SNPs are commonly present in all species including humans. SNP genotyping and analysis technology can analyze thousands of SNPs and has the potential for whole-genome genotyping. It is the most common genetic variation that occurs in the genetic makeup. It is an emerging field in life science, which provides an in-depth analysis of SNPs. It is generally used by researchers for genomics study. It has a broad range of applications in several industries such as Pharmaceuticals and Pharmacogenomics, Diagnostics Research, Agriculture Biotechnology, and Breeding and Animal Livestock. There are several technologies which are used for SNP genotyping and analysis such as SNP GeneChips and microarrays, TaqMan allelic discrimination, SNP by pyrosequencing, SNPlex, and MassARRAY Matrix-assisted Laser Desorption/Ionization-Time-of-Flight. The analysts forecast the Global SNP Genotyping and Analysis market to grow at a CAGR of 20.65 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Market Segmentation by Application 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - Affymetrix Inc. - Illumina Inc. - F. Hoffmann-La Roche Ltd. - Thermo Fisher Scientific Inc. - Agilent Technologies Inc. - Douglas Scientific Llc. - Fluidigm Corp. - Luminex Corp. - PREMIER Biosoft Intl. - Promega Corp - Qiagen N. V. - Sequenom Inc. - WaferGen Biosystems Inc. For more information visit http://www.researchandmarkets.com/research/ct...bal_single
Affymetrix Reports Second Quarter 2014 Operating Results
Business Wire - Thu Jul 31, 3:00PM CDT
Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the second quarter of 2014.
Appointments, New Orders, and Program Expansions - Research Reports on NQ Mobile, Plug Power, Zhone Technologies, Proofpoint and Affymetrix
PR Newswire - Wed Jul 23, 7:10AM CDT
Today, Analysts Review released its research reports regarding NQ Mobile Inc. (NYSE: NQ), Plug Power Inc. (NASDAQ: PLUG), Zhone Technologies Inc. (NASDAQ: ZHNE), Proofpoint, Inc. (NASDAQ: PFPT) and Affymetrix Inc. (NASDAQ: AFFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5017-100free.
Global Transcriptomics Market 2014-2018 with Abbott, Affymetrix, Agilent Technologies, F. Hoffman-La Roche, Illumina & Thermo Fisher Scientific Dominating
M2 - Mon Jul 21, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbvfc/global) has announced the addition of the "Global Transcriptomics Market 2014-2018" report to their offering. The Global Transcriptomics market will grow at a CAGR of 15.8 percent over the period 2013-2018. Transcriptomics studies involve the collection and analysis of transcriptomes of different types of cells or tissues of organism. A transcriptome represents the set of all RNA molecules, which is a small part of the genetic code. The variation in genetic expression characterizes the extensive range of physical and biochemical differences among various cells and tissues and may lead to disease. It helps researchers to understand transcriptional activity in disease cause. Transcriptomics includes four prominent technologies: Microarrays, PCR, RNAi Gene Silencing Technology, and NGS technologies. This report covers the present scenario and the growth prospects of the Global Transcriptomics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of products used for research and diagnostics. The products employed in the use microarray, PCR, NGS and RNAi techniques are considered within the scope of the report. The report, the Global Transcriptomics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions with individual country-wise revenue segmentation; it also covers the Global Transcriptomics market landscape and its growth prospects in the coming years. The report also includes a share of the key vendors operating in this market. Key Vendors - Abbott Laboratories - Affymetrix Inc. - Agilent Technologies Inc. - F. Hoffmann-La Roche Ltd. - Illumina Inc. - Thermo Fisher Scientific Inc. Other Prominent Vendors - Biological Industries Ltd. - Bio-Rad Laboratories Inc. - Cytognomix Inc. - Kreatech Inc. - Molecular Devices LLC - Oxford Gene Technology Ltd. - Qiagen N. V. - SciGene Corp. - Sigma-Aldrich Co. LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/4kbvfc/global
New Licenses, Conference Call Schedules, and Partnerships to Lead Marketing Strategies - Analyst Notes on NetEase, Lattice Semiconductor, Cypress, Affymetrix and ChannelAdvisor
PR Newswire - Thu Jul 10, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding NetEase.com, Inc. (NASDAQ: NTES), Lattice Semiconductor Corporation (NASDAQ: LSCC), Cypress Semiconductor Corporation (NASDAQ: CY), Affymetrix Inc. (NASDAQ: AFFX) and ChannelAdvisor Corporation (NYSE: ECOM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4630-100free.
Shares of AFFX Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 09, 9:24AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on May 12th, 2014 at $7.88. In approximately 2 months, Affymetrix has returned 13.90% as of today's recent price of $8.97.
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Global Flow Cytometry Market Forecasts and Opportunities, 2018: Technology, Products & Services, Application & End User Analysis
M2 - Tue Jul 08, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xsvbl6/flow_cytometry) has announced the addition of the "Global Flow Cytometry Market Forecasts and Opportunities, 2018: Technology, Products & Services, Application & End User Analysis" report to their offering. In this report, the global flow cytometry market has been segmented on the basis of products (instruments, reagents and consumables, software, services, and accessories) and applications (research, clinical, and industrial applications). The Research field commands a major chunk of the global flow cytometry market in 2013. This is attributed to the increasing applications of flow cytometry in drug discovery and development process, right from pre-clinical trials to target identification and throughput screening. However, the clinical applications segment is the fastest growing segment in this market, owing to the increasing prevalence coupled with intensifying adoption of flow cytometry techniques for the diagnosis and treatment of a number of diseases such as cancer, HIV/AIDS, and others. The global flow cytometry market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period (2013-2018). However, the Asia-Pacific region is expected to grow at the highest CAGR of 16% from 2013 to 2018. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as various economic developments and growing prevalence to HIV/AIDS, growing number of research initiatives, increasing government support, growing awareness, and growing focus of both international and domestic players are driving the growth of the market in the Asia-Pacific region. New product launches is the key strategy followed by the leading market players to ensure their growth in the market. Moreover, partnerships, agreements, collaborations and joint ventures, mergers and acquisitions, and expansions are some other growth strategies adopted by the industry players in the global market. Scope Technology - Cell-Based - Bead-Based Products & Services - Reagents - Instruments - Software - Accessories Application - Research - Clinical End User - Commercial Organizations - Diagnostics Laboratories Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Trends 6 Technology 7 Product 8 Application 9 End User 10 Geography 11 Competitive Landscape 12 Company Profiles - Beckman Coulter, Inc. (A Subsidiary Of Danaher Corporation) - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc. - Ebioscience, Inc. (A Subsidiary Of Affymetrix, Inc.) - Emd Millipore Corporation (A Division Of Merck Kgaa) - Life Technologies Corporation (A Brand Of Thermo Fisher Scientific, Inc.) - Luminex Corporation - Miltenyi Biotech - Partec Gmbh - Ttp Labtech Ltd. For more information visit http://www.researchandmarkets.com/research/xs..._cytometry
Synta Pharmaceuticals (SNTA) Jumps: Stock Rises 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 8:21AM CDT
Synta Pharmaceuticals Corp. (SNTA) was a big mover last session, as the company saw its shares rise by almost 8% on the day.
Affymetrix to Report Second Quarter 2014 Operating Results on Thursday July 31, 2014
Business Wire - Mon Jul 07, 5:00AM CDT
Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will report operating results for the second quarter of 2014 after market close on Thursday July 31, 2014. The company will hold a conference call on the same day at 5:00pm ET.
Genomic Grows on Breast Cancer Test, Margin Pressure Continues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 1:30PM CDT
On Jul 3, we issued an updated research report on Genomic Health Inc. (GHDX).
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Global Molecular Cytogenetics Market 2014-2018 with Abbott Labs, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina & PerkinElmer Dominating
M2 - Wed Jul 02, 2:03PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ssrz43/global_molecular) has announced the addition of the "Global Molecular Cytogenetics Market 2014-2018 with Abbott Labs, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina & PerkinElmer Dominating" report to their offering. The Global Molecular Cytogenetics Market will grow at a CAGR of 23.51% to 2018 This report covers the present scenario and the growth prospects of the Global Molecular Cytogenetics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of products used in molecular cytogenetics. The products employed in the use of FISH and aCGH techniques are considered within the scope of the report. The increase in the incidence of genetic disorders is one of the major drivers. Genetic disorders such as Down syndrome, fragile X syndrome, tuberous sclerosis, and other genetic and chromosomal disorders have increased the demand for cytogenetic diagnostic kits and technology. Molecular cytogenetic techniques can be used in personalized medicines for the early detection of diseases and selection of appropriate treatment, integration of molecular diagnostics with therapeutics, and monitoring therapy, as well as determining the prognosis. At present, cytogenetic analysis allows the study of essential biological problems such as the nature of inherited syndromes and genomic variations, which are responsible for carcinogenesis and 3D organization of the human genome. Identification and validation of the genetic composition of an individual plays a major part in ascertaining health and susceptibility to common diseases such as heart disease and cancer. The awareness of genetic diseases is helping in the development of personalized medicines, which are focused on targeted drug development. Genetic profiling of patients helps in defining an individual's risk for clinical outcomes and his/her response to specific drugs. Personalized medicines are highly effective and help improve the health of a patient. Further, the report states that one of the major challenges in the market is the lack of knowledge about genomics among doctors and researchers, which leads to misinterpretation of the genetic data of an individual. Key Vendors - Abbott Laboratories - Affymetrix Inc. - Agilent Technologies Inc. - F. Hoffmann-La Roche Ltd - Illumina Inc. - PerkinElmer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/ss..._molecular
Dicerna Pharmaceuticals (DRNA) Soars: Stock Rises 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:39AM CDT
Dicerna Pharmaceuticals, Inc. (DRNA) was a big mover last session, as its shares rose almost 20% on the day.
Curis (CRIS) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:51AM CDT
Curis, Inc. (CRIS) was a big mover last session, as its shares rose over 11% on the day.
BIND Therapeutics (BIND) Soars: Stock Adds 9.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:39AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as its shares rose over 9% on the day.
Dyax Corp. (DYAX) Soars: Stock Rises 12.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 7:51AM CDT
Dyax Corp. (DYAX) was a big mover last session, as its shares rose nearly 13% on the day.
Affymetrix Up 14.7% Since SmarTrend Uptrend Call (AFFX)
Comtex SmarTrend(R) - Fri Jun 27, 11:49AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on May 12th, 2014 at $7.88. In approximately 2 months, Affymetrix has returned 14.67% as of today's recent price of $9.03.
Earnings Estimates Moving Higher for Affymetrix (AFFX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:40AM CDT
Affymetrix could be a solid choice for investors, as it witnessed solid earnings estimate revision activity and also has a favorable Zacks Rank.
Cell Culture: The Market for Media, Sera and Reagents to 2017
M2 - Thu Jun 26, 2:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pqnpcm/cell_culture_the) has announced the addition of the "Cell Culture: The Market for Media, Sera and Reagents" report to their offering. The choice of cells to use in biopharmaceutical production depends on a number of factors, some technical and some economic. Bacteria and yeast, for instance, are relatively simple to grow. Each cell of a bacterium or yeast is an independent organism capable of its own metabolism. Yeasts and bacteria have fairly simple nutritional needs and grow well suspended in a liquid medium, as well as in large fermentors. This report is focused on cell culture used in the research and production of biopharmaceuticals. In the pharmaceutical industry, cell culture is a major foundation of biopharmaceutical development, bioprocessing and manufacturing. Biopharmaceutical products are developed from large, complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. As growing cells for biopharmaceutical production is slow, expensive and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals. Forecasts and current market sizing are provided in three specific segments: Media, Sera, and Reagents exhaustive report provides specific information on: - Market Size, of the Cell Culture Media Segment Market, Sera Segment Market and Reagent Segment Market through 2017 - Market Share Estimate for Animal-Derived, Component Free Media - Market Share Estimate for Serum-Free Media - Market Share Estimate for Chemically-Defined Media - Competitive Market Share by leading supplier as of 2012 - Estimated Market by Region (North America, Europe, Asia U.S.) - Key Market Drivers and Restraints for suppliers, including discussions of biopharmaceutical pipelines, biomedical R&D directions, and the future of transgenic plant and animal production. - Review of the various expression systems (Bacteria, Yeast, Insect, and Mammal) and the biopharmaceutical product manufactured by these systems The report contains a discussion of the preferences in media types vying for dominance in the market, including the following: - ADCF - animal derived component free media - CD - chemically defined media - CSFM - complete serum free medium - PF - protein free media - SF - serum free media - SFM - serum free medium Key Topics Covered: CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER TWO: GENETICALLY MODIFIED CELLS FOR BIOPHARMACEUTICAL DEVELOPMENT CHAPTER THREE: CELL CULTURE TECHNOLOGY CHAPTER FOUR: CELL CULTURE MARKET CURRENT AND FUTURE TRENDS CHAPTER FIVE: COMPANY PROFILES - Advanced Biotechnologies, Inc. - Affymetrix, Inc. - AMRESCO, Inc. - Atlanta Biologicals, Inc. - BD Biosciences - Bioreclamation Inc - Cell Essentials, Inc. - CellGenix Technologie Transfer GmbH - ClonTech Laboratories, inc. - Corning Life Sciences - EMD Millipore - GE Healthcare Live Sciences - Gemini Bio-Products - Invitria - Irvine Scientific - J R Scientific, Inc. - Life Technologies Corporation - Lonza Bioscience - MP Biomedicals - Novozymes Biopharma US Inc - PromoCell GmbH - Quality Biological, Inc. - R&D Systems, Inc. - SAFC Biosciences - SBH Sciences - Selexis SA - SeraCare Life Sciences, Inc. - Sera Laboratories International Ltd - Stemcell Technologies Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/pq...ulture_the
